Orano Med's ambition is to develop a new generation of targeted cancer therapies thanks to the unique properties of lead-212 ( 212 Pb), a very rare alpha-emitting radioisotope.
Although research in oncology has made enormous progress in recent years, the medical needs for a wide range of cancers remain unmet. Our approach, better known as targeted alpha therapy, has the potential to bring significant benefits to patients who have not responded to existing treatments.